COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
October 04, 2022 09:05 ET
|
COMPASS Pathways
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
September 19, 2022 16:01 ET
|
COMPASS Pathways
LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in three upcoming investor events
September 01, 2022 08:06 ET
|
COMPASS Pathways
LONDON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
August 04, 2022 07:00 ET
|
COMPASS Pathways
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Highlights: Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 phase II study in...
COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
August 02, 2022 16:05 ET
|
COMPASS Pathways
LONDON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference
August 01, 2022 08:00 ET
|
COMPASS Pathways
LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
July 28, 2022 04:00 ET
|
COMPASS Pathways
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...
COMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
July 26, 2022 08:00 ET
|
COMPASS Pathways
LONDON, July 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
July 19, 2022 08:00 ET
|
COMPASS Pathways
Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care George Goldsmith remains...
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
May 23, 2022 07:00 ET
|
COMPASS Pathways
Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...